Your browser doesn't support javascript.
loading
Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Salama, Engie; Hill, Lucas; Patel, Nimish; Best, Brookie M; Momper, Jeremiah D.
Afiliação
  • Salama E; University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; and.
  • Hill L; University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; and.
  • Patel N; University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; and.
  • Best BM; University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; and.
  • Momper JD; Pediatrics Department, University of California San Diego-Rady Children's Hospital San Diego, San Diego, CA.
J Acquir Immune Defic Syndr ; 88(4): 389-392, 2021 12 01.
Article em En | MEDLINE | ID: mdl-34285156
ABSTRACT

BACKGROUND:

Bictegravir coformulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination (BIC/FTC/TAF 50/200/25 mg) is recommended as an initial regimen in patients who are antiretroviral (ARV)-naïve or virologically suppressed on a stable ARV regimen. However, no real-world pharmacokinetic (PK) data are available in treatment-experienced patients with antiretroviral resistance receiving BIC/FTC/TAF plus a boosted protease inhibitor. SETTING/

METHODS:

This prospective, single-center, nonrandomized pharmacokinetic study enrolled adult treatment-experienced persons with HIV and creatinine clearance >30 mL/min receiving BIC/FTC/TAF + DRV/c as part of routine clinical care. Steady-state PK profiles of BIC, TAF, tenofovir (TFV), and DRV after daily dosing of BIC/FTC/TAF + darunavir/cobicistat (DRV/c) were obtained with samples at predose and 0.5, 1, 2, and 4 hours postdose. The AUC0-24 at steady state was extrapolated by imputing C0 for C24 for each participant (AUC0-tau,exp).

RESULTS:

Nine participants were enrolled with a median age of 59 years (range 54-67) and median number of years on ART of 19 (range 5.8-30). The median (interquartile range [IQR]) BIC AUC0-tau,exp and Cmax values were 128.9 µg*h/mL (78.1-159.5) and 6.9 µg/mL (5.1-9.8), respectively. The median (IQR) TAF AUC0-tau,exp and Cmax values were 0.376 µg*h/mL (0.199-0.430) and 0.276 µg/mL (0.149-0.543), respectively. Predose concentrations of TFV and DRV were comparable with historical data.

CONCLUSION:

Treatment-experienced persons with HIV receiving BIC/FTC/TAF + darunavir/cobicistat (DRV/c) had BIC exposures (AUC0-tau) that were increased by approximately 26% compared with historical PK data. Although TAF exposures were substantially increased, plasma TFV was only modestly higher. These results suggest that BIC/TAF/FTC + DRV/c is a viable antiviral regimen option for treatment-experienced persons.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Piridonas / Infecções por HIV / Fármacos Anti-HIV / Darunavir / Cobicistat / Tenofovir / Amidas / Compostos Heterocíclicos com 3 Anéis Tipo de estudo: Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Acquir Immune Defic Syndr Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Piridonas / Infecções por HIV / Fármacos Anti-HIV / Darunavir / Cobicistat / Tenofovir / Amidas / Compostos Heterocíclicos com 3 Anéis Tipo de estudo: Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Acquir Immune Defic Syndr Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2021 Tipo de documento: Article